Tiziana Life Sciences completes patient visits in MS drug trial

Tiziana Life Sciences reported the last patient completed the final visit in its Phase 2a INFORM-MS trial of intranasal foralumab in progressive multiple sclerosis. Topline 12-week treatment results have not been presented yet; release is scheduled for October following a database lock this week.